Processing

Please wait...

Settings

Settings

Goto Application

1. EP2388012 - Kisspeptin peptides for use in the treatment of Alzheimer's disease, Creutzfeldt-Jakob disease or diabetes mellitus

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]
Claims

1. A peptide comprising the amino acid sequence defined herein as SEQ ID No. 2, for use in the treatment of a condition associated with Amyloid fibril-forming peptides, wherein the peptide does not directly activate or inhibit the GPR-54 G-protein coupled receptor.
  2. A peptide according to claim 1, wherein the condition is Alzheimer's disease.
  3. A peptide according to claim 1, wherein the condition is Creutzfeldt-Jakob disease.
  4. A peptide according to claim 1, wherein the condition is diabetes mellitus.
  5. A peptide comprising the amino acid sequence defined herein as SEQ ID No. 11, for use in the treatment of a condition associated with Aß toxicity.
  6. A peptide according to any of claims 1 to 5, wherein the peptide comprises a first part that consists of amino acid sequence defined herein as SEQ ID No. 2 and optionally a second part which comprises a signal sequence.
  7. A peptide according to any of claims 1 to 5, wherein the peptide comprises a first part which consists of any of the amino acid sequences defined herein as SEQ ID Nos. 4 to 6, and optionally a second part which comprises a signal sequence.
  8. A peptide as defined in any of claims 1, 6 and 7, comprising a detectable label.
  9. A peptide according to claim 8, wherein the label is a fluorophore or biotin.
  10. An antibody having affinity against a peptide defined in claim 1, 6, 7 or 8 for use in the treatment of a condition associated with Amyloid fibril-forming peptides.
  11. An antibody according to claim 10, wherein the condition is as defined in any of claims 2 to 4.
  12. A composition comprising a peptide as defined in any of claims 1, 5, 6, 7, 8 or 9, in a pharmaceutically-acceptable diluent.
  13. An in vitro method for determining whether a subject has, or is predisposed to having, a disorder associated with Amyloid formation, comprising treating a sample from the subject with a peptide as defined in any of claims 1, 5, 6, 7 or 8 or an antibody as defined in claim 10, to determine whether the sample comprises Amyloid fibril-forming peptides.
  14. A method according to claim 13, wherein the peptide or antibody is detectably-labelled.